Immunological Medicine最新文献_第8页

Homeostasis and immunological function of self-driven memory-phenotype CD4⁺ T lymphocytes. 自我驱动记忆表型CD4+ T淋巴细胞的稳态和免疫功能。

IF 4.4

Immunological Medicine Pub Date : 2023-03-01 DOI: 10.1080/25785826.2022.2129370

Takeshi Kawabe

{"title":"Homeostasis and immunological function of self-driven memory-phenotype CD4+ T lymphocytes.","authors":"Takeshi Kawabe","doi":"10.1080/25785826.2022.2129370","DOIUrl":"https://doi.org/10.1080/25785826.2022.2129370","url":null,"abstract":"CD4+ T lymphocytes play an essential role in adaptive immune responses. In pathogen infection, naïve CD4+ T cells that strongly respond to foreign antigens robustly proliferate to differentiate into effector/memory cells, contributing to elimination of the pathogen concerned. In addition to this conventional T cell activation pathway, naïve T cells can also weakly respond to self antigens in the periphery to spontaneously acquire a memory phenotype through homeostatic proliferation in steady state. Such 'memory-phenotype' (MP) CD4+ T lymphocytes are distinguishable from foreign antigen-specific memory cells in terms of marker expression. Once generated, MP cells are maintained by rapid proliferation while differentiating into the T-bet+ 'MP1' subset, with the latter response promoted by IL-12 homeostatically produced by type 1 dendritic cells. Importantly, MP1 cells possess innate immune function; they can produce IFN-γ in response to IL-12 and IL-18 to contribute to host defense against pathogens. Similarly, the presence of RORγt+ 'MP17' and Gata3hi 'MP2' cells as well as their potential immune functions have been proposed. In this review, I will discuss our current understanding on the unique mechanisms of generation, maintenance, and differentiation of MP CD4+ T lymphocytes as well as their functional significance in various disease conditions.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10687004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

IF 4.4

Immunological Medicine Pub Date : 2023-03-01 DOI: 10.1080/25785826.2023.2152540

引用次数: 1

Immune response induced in rodents by anti-CoVid19 plasmid DNA vaccine via pyro-drive jet injector inoculation. 高温驱动喷射器接种抗covid - 19质粒DNA疫苗诱导啮齿动物免疫应答

IF 4.4

Immunological Medicine Pub Date : 2022-12-01 Epub Date: 2022-08-24 DOI: 10.1080/25785826.2022.2111905

Tomoyuki Nishikawa, Chin Yang Chang, Jiayu A Tai, Hiroki Hayashi, Jiao Sun, Shiho Torii, Chikako Ono, Yoshiharu Matsuura, Ryoko Ide, Junichi Mineno, Miwa Sasai, Masahiro Yamamoto, Hironori Nakagami, Kunihiko Yamashita

{"title":"Immune response induced in rodents by anti-CoVid19 plasmid DNA vaccine via pyro-drive jet injector inoculation.","authors":"Tomoyuki Nishikawa, Chin Yang Chang, Jiayu A Tai, Hiroki Hayashi, Jiao Sun, Shiho Torii, Chikako Ono, Yoshiharu Matsuura, Ryoko Ide, Junichi Mineno, Miwa Sasai, Masahiro Yamamoto, Hironori Nakagami, Kunihiko Yamashita","doi":"10.1080/25785826.2022.2111905","DOIUrl":"https://doi.org/10.1080/25785826.2022.2111905","url":null,"abstract":"There is an urgent need to stop the coronavirus disease 2019 (COVID-19) pandemic through the development of efficient and safe vaccination methods. Over the short term, plasmid DNA vaccines can be developed as they are molecularly stable, thus facilitating easy transport and storage. pVAX1-SARS-CoV2-co was designed for the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) S protein. The antibodies produced led to immunoreactions against the S protein, an anti-receptor-binding-domain, and a neutralizing action of the pVAX1-SARS-CoV2-co, as previously confirmed. To promote the efficacy of the pVAX1-SARS-CoV2-co vaccine a pyro-drive jet injector (PJI) was used. An intradermally adjusted PJI demonstrated that the pVAX1-SARS-CoV2-co vaccine injection caused a high production of anti-S protein antibodies, triggered immunoreactions, and neutralized the actions against SARS-CoV-2. A high-dose pVAX1-SARS-CoV2-co intradermal injection using PJI did not cause any serious disorders in the rat model. A viral challenge confirmed that intradermally immunized mice were potently protected from COVID-19. A pVAX1-SARS-CoV2-co intradermal injection using PJI is a safe and promising vaccination method for overcoming the COVID-19 pandemic.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40422100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Istradefylline, an adenosine A2a receptor antagonist, inhibits the CD4⁺ T-cell hypersecretion of IL-17A and IL-8 in humans. isstradefylline是一种腺苷A2a受体拮抗剂，可抑制人CD4+ t细胞分泌IL-17A和IL-8。

IF 4.4

Immunological Medicine Pub Date : 2022-12-01 Epub Date: 2022-07-05 DOI: 10.1080/25785826.2022.2094593

Mieko Tokano, Masaaki Kawano, Rie Takagi, Sho Matsushita

{"title":"Istradefylline, an adenosine A2a receptor antagonist, inhibits the CD4+ T-cell hypersecretion of IL-17A and IL-8 in humans.","authors":"Mieko Tokano, Masaaki Kawano, Rie Takagi, Sho Matsushita","doi":"10.1080/25785826.2022.2094593","DOIUrl":"https://doi.org/10.1080/25785826.2022.2094593","url":null,"abstract":"Extracellular adenosine produced from ATP plays a role in energy processes, neurotransmission, and inflammatory responses. Istradefylline is a selective adenosine A2a receptor (A2aR) antagonist used for the treatment of Parkinson's disease. We previously showed using mouse models that adenosine primes hypersecretion of interleukin (IL)-17A via A2aR, which plays a role in neutrophilic inflammation models in mice. This finding suggests that adenosine is an endogenous modulator of neutrophilic inflammation. We, therefore, investigated the in vitro effect of istradefylline in humans. In the present study, using human peripheral blood mononuclear cells (PBMCs), we tested the effect of adenosine, adenosine receptor agonists and istradefylline on cytokine responses using mixed lymphocyte reaction (MLR), PBMCs, CD4+ T cells, and Candida albicans antigen (Ag)-stimulated PBMCs. We showed that adenosine and an A2aR agonist (PSB0777) promoted IL-17A and IL-8 production from human PBMCs, and istradefylline suppressed this response. In addition, istradefylline inhibited not only the IL-17A and IL-8 production induced by adenosine but also that from C. albicans Ag-stimulated PBMCs. These results indicate that adenosine-mediated IL-17A and IL-8 production plays a role in neutrophilic inflammation, against which istradefylline should be effective.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40473886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Serum B cell activating factor (BAFF) as a biomarker for induction of remission with rituximab in ANCA-associated vasculitis. 血清B细胞活化因子(BAFF)作为利妥昔单抗诱导anca相关血管炎缓解的生物标志物。

IF 4.4

Immunological Medicine Pub Date : 2022-12-01 Epub Date: 2022-07-08 DOI: 10.1080/25785826.2022.2094592

Kazuyuki Tsuboi, Kazuteru Noguchi, Masayasu Kitano, Tetsuya Furukawa, Teppei Hashimoto, Naoto Azuma, Kiyoshi Matsui

{"title":"Serum B cell activating factor (BAFF) as a biomarker for induction of remission with rituximab in ANCA-associated vasculitis.","authors":"Kazuyuki Tsuboi, Kazuteru Noguchi, Masayasu Kitano, Tetsuya Furukawa, Teppei Hashimoto, Naoto Azuma, Kiyoshi Matsui","doi":"10.1080/25785826.2022.2094592","DOIUrl":"https://doi.org/10.1080/25785826.2022.2094592","url":null,"abstract":"We examined whether serum B cell activating factor (BAFF) is useful for predicting the remission of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) following rituximab treatment. We used the Birmingham Vasculitis Activity Score (BVAS) 2008 version 3 for the evaluation of 27 patients with AAV 6 months after rituximab treatment. Those with BVAS = 0 achieved remission, whereas those with BVAS score > 0 did not achieve remission. We considered changes in serum BAFF before rituximab treatment, 1 month after treatment, and 6 months after treatment. In the remission group, the serum BAFF increased consistently. In the non-achieved group, serum BAFF was within the normal range. In addition, there was no statistically significant difference between the two groups in terms of serum BAFF before and 1 month after rituximab treatment. However, the serum BAFF level at 6 months after rituximab treatment was significantly higher in the remission group than in the non-achieved group. If serum BAFF does not increase after 6 months of rituximab in AAV, it may be assumed that there are residual B cells and plasma cells in the tissues. Enhanced treatment targeting B cells, including re-administration of rituximab or the addition of other immunosuppressive drugs, should be considered.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40494776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiotherapy driven immunomodulation of the tumor microenvironment and its impact on clinical outcomes: a promising new treatment paradigm. 放疗驱动肿瘤微环境的免疫调节及其对临床结果的影响:一种有希望的新治疗模式。

IF 4.4

Immunological Medicine Pub Date : 2022-09-01 Epub Date: 2021-10-27 DOI: 10.1080/25785826.2021.1997268

Umair Mahmood

引用次数: 1

Management of inflammatory bowel disease during the COVID-19 pandemic. COVID-19大流行期间炎症性肠病的管理。

IF 4.4

Immunological Medicine Pub Date : 2022-09-01 Epub Date: 2021-09-16 DOI: 10.1080/25785826.2021.1978205

Tadakazu Hisamatsu

{"title":"Management of inflammatory bowel disease during the COVID-19 pandemic.","authors":"Tadakazu Hisamatsu","doi":"10.1080/25785826.2021.1978205","DOIUrl":"https://doi.org/10.1080/25785826.2021.1978205","url":null,"abstract":"The COVID-19 pandemic, caused by novel coronavirus SARS-CoV-2, has had an enormous impact on public health, medical systems, economies, and social conditions. The pandemic has also greatly influenced medical care systems for patients with inflammatory bowel disease (IBD). Establishment of a global registry system and accumulated experiences have led to consensus for IBD management under the COVID-19 pandemic. IBD itself does not pose an increased risk of SARS-CoV-2 infection or aggravation of COVID-19, and immune-control treatments other than systemic steroids, such as biologics, are unlikely to increase this risk. The importance of suppressing disease activity has not changed since before the pandemic. The effects of the COVID-19 pandemic on behavioral changes and psychological states among patients have various results and differ by country or region as well as between adult and pediatric patients. In future, information-sharing tools that can widely and correctly disseminate the views of experts will be very important. Vaccination remains in its infancy, but the impact of immunoregulatory therapy on antibody titers must be investigated. Information about COVID-19 is constantly being updated, and new and accurate medical care updates are needed. In Japan, the Japan COVID-19 Taskforce contributes to information dissemination, patient registries, and clinical research.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39423120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Signaling via dopamine and adenosine receptors modulate viral peptide-specific and T-cell IL-8 response in COVID-19. 在COVID-19中，通过多巴胺和腺苷受体的信号传导调节病毒肽特异性和t细胞IL-8反应。

IF 4.4

Immunological Medicine Pub Date : 2022-09-01 DOI: 10.1080/25785826.2022.2079369

Mieko Tokano, Rie Takagi, Masaaki Kawano, Shigefumi Maesaki, Norihito Tarumoto, Sho Matsushita

{"title":"Signaling via dopamine and adenosine receptors modulate viral peptide-specific and T-cell IL-8 response in COVID-19.","authors":"Mieko Tokano, Rie Takagi, Masaaki Kawano, Shigefumi Maesaki, Norihito Tarumoto, Sho Matsushita","doi":"10.1080/25785826.2022.2079369","DOIUrl":"https://doi.org/10.1080/25785826.2022.2079369","url":null,"abstract":"B-cell but not T-cell responses have been extensively studied using peripheral blood mononuclear cells (PBMCs) obtained from patients with coronavirus disease 2019 (COVID-19). Our recent study showed that not only T-helper (Th) 17 but also Th1 cells directly produce interleukin (IL)-8, a major source of neutrophilic inflammation, which is also known to induce disseminated intravascular coagulation (DIC) in COVID-19 patients. Neutrophilic inflammation caused by IL-17A or IL-8 can be fatal; thus, therapeutic intervention is highly expected. The present study aimed to investigate the T-cell responses in the Japanese patients. We synthesized spike protein-derived 15-mer peptides that are expected to bind to HLA class II allelic products frequently observed in the Japanese population, and checked the T-cell responses in Japanese patients with COVID-19. We have found that (i) patients show marked IL-8 but not IL-17A responses; (ii) these responses are restricted by HLA-DR; and (iii) IL-8 responses are abrogated by a dopamine D2 like receptor (D2R) agonist, ropinirole, and an adenosine A2a receptor (A2aR) antagonist, istradefylline. Compounds used for the treatment of Parkinson's disease may ease DIC in COVID-19. (183 words).","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9630616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Lessons from transmissible cancers for immunotherapy and transplant. 传染性癌症对免疫治疗和移植的启示。

IF 4.4

Immunological Medicine Pub Date : 2022-09-01 Epub Date: 2021-12-28 DOI: 10.1080/25785826.2021.2018783

Rafael Cardoso Maciel Costa Silva, Carolina Panis, Bruno Ricardo Barreto Pires

引用次数: 1

B-cell depletion therapy for multiple sclerosis. b细胞消耗疗法治疗多发性硬化症。

IF 4.4

Immunological Medicine Pub Date : 2022-06-01 Epub Date: 2021-07-21 DOI: 10.1080/25785826.2021.1952543

Yusei Miyazaki, Masaaki Niino

{"title":"B-cell depletion therapy for multiple sclerosis.","authors":"Yusei Miyazaki, Masaaki Niino","doi":"10.1080/25785826.2021.1952543","DOIUrl":"https://doi.org/10.1080/25785826.2021.1952543","url":null,"abstract":"Since the initial observation of increased immunoglobulin concentrations in the cerebrospinal fluid of multiple sclerosis (MS) patients in the 1940s, B cells have been considered to participate in the pathology of MS through the production of autoantibodies reactive against central nervous system antigens. However, it is now recognized that B cells contribute to MS relapses via antibody-independent activities, including the presentation of antigens to T cells and the release of pro-inflammatory cytokines. In addition, the recent identification of B cell-rich follicle-like structures in the meninges of progressive MS patients suggests that the pathogenic roles of B cells also exist at the progressive phase of this disease. Recently, large-scale clinical trials have demonstrated the efficacy of B-cell depletion therapy using anti-CD20 antibodies in relapsing as well as primary progressive MS. B-cell depletion therapy has become an essential treatment option for MS based on its unique benefit to risk balance in relapsing MS, and because it is the only drug that has been shown to be effective in primary progressive MS to date.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/25785826.2021.1952543","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39209598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7